RE:RE:Share concentrationLongRVXer, I just re-read your Mar 13th post because it kept floating around in my head.
As I always say I'm not a trader and I don't fully grasp ledrog and your understandings of shorters and traders but your reference back to the post ASSURE July 2013 trading I understand what you are saying because even though I never sold a share had I had the resources at the time I would have bought in massively (and made 400% or more in a couple of weeks and much more in a few months). Hind sight is 20 x 20 as they say!
So perhaps what has me thinking is BDAZ's link back to 2013 on the ASSURE results....https://www.resverlogix.com/media/press-release.html?id=492#.WMlHlxLyu7q
Study this press release very carefully. Then add to that todays announcement of patent confirmation of what appears to be at least a couple of treatment patents;
- apabetalone + rosuvastatin in 1 pill
- apabetalone and rosuvastatin in a treatment regime administered separately but as a system of treatment with patients with low HDL, CVD including those with CKD and also the group with diabetes mellitus.
On the share/trading side based on your post if I understand it properly the 40,000,000 so called "loosely held" shares are probably held by longs. Now this is just a hunch of course. So there are probably very few liquid shares available at these extremely low prices.
So it strikes me that I am not sure how to describe it but it is sort of like a volcano where the pressure is building and it could erupt before BETonMACE results in 2018 with longs of all types, those that want $5, those that want $10 those that want $100. From my perspective, the reference system I am guessing at is what I think is the reference systems of Eastern, NGN, Don, CV Ventures and that is big, IMHO. These investors can handle all or none. And we know from the 2013 experience and all of the subsequent learning that there is a huge amount of intellectual (IP) value that already exists. We know some of the markets are huge and growing throughout the world and I believe we know the payer model will probably work and we probably know this would be ongoing chronic treatment.
The reason I say the volcano could erupt ahead of BETonMACE is because the understanding of the MOA has been so rapid.
So perhaps if I was an investor attending Cowen, given that the apabetalone futility analysis will be in just a few months and BETonMACE will be mid 2018 and given the MOA findings I may well jump in at these price levels.
Doesn't leave much liquidity for the traders though...just a very tightly held bunch of shares by longs like me.
Oh well, just thinking out loud.
DYODD GLTA
Toinv